SLC9A3 and cancer: While the impact of hypomethylation at cg18447419 on the action of AHR-mediated RhoA/Rac1 signaling is unknown, this CpG and SLC9A3 should be considered in future candidate analyses given the known interaction between this pathway and dioxin and its potential role in diseases like cancer.